INTRON A VS INTRON A + RIBAVIRIN IN RELAPSED HEPATITIS C

本研究针对干扰素α-2b的有效性和安全性进行了研究。 丙型肝炎患者与干扰素α-2b和利巴韦林的比较 之前对干扰素有反应但治疗后复发的人 被阻止了。对治疗的生化和病毒学反应是 在两个时间点测量：治疗结束时和六个月 治疗后持续有效。次要终端包括 治疗后肝活检的改善、起效时间和时间 故态复萌。基于这些标记物，这项随机临床试验 初步数据显示，综合治疗带来了 与26%-30%的持续响应相比，持续响应提高了50%-60% 单独使用干扰素α2b。未来的研究将集中在是否需要 在最初的治疗过程中提供最佳治疗 关于对复发的初始应答者进行再治疗的发现 与治疗反应比以前低的相关 据报道。

This study addresses the efficacy and safety of interferon alpha-2b compared to interferon alpha-2b and ribavirin in hepatitis C patients who had previously responded to interferon but relapsed after therapy was stopped. The biochemical and virological response to treatment are measured at two time points: at the end of treatment and six months posttreatment sustained response. Secondary endpoints include improvement in liver biopsy at posttreatment, time to response and time to relapse. Based on these markers, this randomized clinical trial preliminary data suggests the treatment with combined therapy brings improvement in sustained responses of 50-60% compared to 26-30% of interferon alpha 2b alone. Future studies will focus on the need to provide optimal treatment during the initial course of therapy based on the finding that retreatment of initial responders who relapse is associated with a lower end of treatment response than previously reported.